PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21383241-5	2011	CP-690,550 inhibited IL-4-dependent Th2 cell differentiation and interestingly also interfered with Th17 cell differentiation.	tofacitinib	0-6	interleukin 4	Mus musculus	21-25	
21383241-5	2011	CP-690,550 inhibited IL-4-dependent Th2 cell differentiation and interestingly also interfered with Th17 cell differentiation.	tofacitinib	0-6	heart and neural crest derivatives expressed 2	Mus musculus	36-39	
21383241-8	2011	Moreover, CP-690,550 also prevented the activation of STAT1, induction of T-bet, and subsequent generation of Th1 cells.	tofacitinib	10-16	signal transducer and activator of transcription 1	Mus musculus	54-59	
21383241-8	2011	Moreover, CP-690,550 also prevented the activation of STAT1, induction of T-bet, and subsequent generation of Th1 cells.	tofacitinib	10-16	T-box 21	Mus musculus	74-79	
21383241-8	2011	Moreover, CP-690,550 also prevented the activation of STAT1, induction of T-bet, and subsequent generation of Th1 cells.	tofacitinib	10-16	negative elongation factor complex member C/D, Th1l	Mus musculus	110-113	
21383241-9	2011	In a model of established arthritis, CP-690,550 rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue.	tofacitinib	37-43	signal transducer and activator of transcription 1	Mus musculus	144-149	
21383241-11	2011	CP-690,550 also modulated innate responses to LPS in vivo through a mechanism likely involving the inhibition of STAT1 signaling.	tofacitinib	0-6	signal transducer and activator of transcription 1	Mus musculus	113-118	
21383241-12	2011	Thus, CP-690,550 may improve autoimmune diseases and prevent transplant rejection by suppressing the differentiation of pathogenic Th1 and Th17 cells as well as innate immune cell signaling.	tofacitinib	6-12	negative elongation factor complex member C/D, Th1l	Mus musculus	131-134